Drug Trial Radar · NCT01121536
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Last checked: Nov 20, 2026Latest source record: Sep 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
867
Actual
Start
Apr 30, 2010
Primary completion
Oct 31, 2013
Study completion Oct 31, 2013
Sponsor
- Lead sponsor
- CephalonIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of long term (6 months) armodafinil treatment as adjunctive therapy to mood-stabilizing medications in adults with bipolar I disorder.
Conditions
- Depression
Interventions
ArmodafinilDrug
Armodafinil tablets, taken orally, once daily in the morning
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Treatment-Emergent Adverse Events (TEAE)Time frame: Day 1 up to Month 6
- Participants With Clinically Significant Abnormal Serum Chemistry ValuesTime frame: Day 1 to Month 6
- Participants With Clinically Significant Abnormal Hematology ValuesTime frame: Day 1 to Month 6
- Participants With Clinically Significant Abnormal Urinalysis ValuesTime frame: Day 1 to Month 6
- Participants With Clinically Significant Abnormal Vital Signs ValuesTime frame: Day 1 to Month 6
- Change From Baseline to Endpoint in Electrocardiogram (ECG) ValuesTime frame: Day 0 (baseline), Month 6 or last post-baseline observation
- Physical Examination Shifts From Baseline to EndpointTime frame: Day 0 (baseline), Month 6 (or last post-baseline observation)
- Change From Baseline to Endpoint in Body WeightTime frame: Day 0 (baseline), Month 6 (or last post-baseline observation)
- Change From Baseline to Endpoint in the Young Mania Rating Scale (YMRS) Total ScoreTime frame: Day 0 (baseline), Month 6 or last post-baseline observation
- Participants With Findings During the Open-Label Study on the Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV)Time frame: Day 1, Week 1, Months 1, 2, 4 and 6 or last post-baseline visit
- Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total ScoreTime frame: Day 0 (baseline), Month 6 (or last post-baseline observation)
- Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total ScoreTime frame: Day 0 (baseline), Month 6 or last post-baseline observation
Locations
158 sites in 17 countries. Site status is shown where the registry gives one.
Teva Investigational Site 113
Birmingham, Alabama
Teva Investigational Site 225
Birmingham, Alabama
Teva Investigational Site 229
Anaheim, California
Teva Investigational Site 217
Cerritos, California
Teva Investigational Site 223
Cerritos, California
Teva Investigational Site 115
Garden Grove, California
Teva Investigational Site 121
Imperial, California
Teva Investigational Site 303
Oceanside, California
Teva Investigational Site 400
Oceanside, California
Teva Investigational Site 200
Pico Rivera, California
Teva Investigational Site 128
San Diego, California
Teva Investigational Site 201
San Diego, California
Teva Investigational Site 192
Santa Ana, California
Teva Investigational Site 292
Santa Ana, California
Teva Investigational Site 295
Sherman Oaks, California
Teva Investigational Site 122
Temecula, California
Teva Investigational Site 131
Gainesville, Florida
Teva Investigational Site 132
Jacksonville, Florida
Teva Investigational Site 606
Jacksonville Beach, Florida
Teva Investigational Site 127
Lauderhill, Florida
Teva Investigational Site 119
North Miami, Florida
Teva Investigational Site 118
Tampa, Florida
Teva Investigational Site 608
Tampa, Florida
Teva Investigational Site 205
Atlanta, Georgia
Teva Investigational Site 116
Atlanta, Georgia
Teva Investigational Site 204
Smyrna, Georgia
Teva Investigational Site 107
Naperville, Illinois
Teva Investigational Site 301
Naperville, Illinois
Teva Investigational Site 219
Oakbrook Terrace, Illinois
Teva Investigational Site 195
Park Ridge, Illinois
Teva Investigational Site 600
Lafayette, Indiana
Teva Investigational Site 300
Pikesville, Maryland
Teva Investigational Site 603
Watertown, Massachusetts
Teva Investigational Site 290
Flowood, Mississippi
Teva Investigational Site 133
St Louis, Missouri
Teva Investigational Site 103
Mount Laurel, New Jersey
Teva Investigational Site 212
Mount Laurel, New Jersey
Teva Investigational Site 193
Albuquerque, New Mexico
Teva Investigational Site 207
Brooklyn, New York
Teva Investigational Site 104
Brooklyn, New York
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.